Schüpbach, A.; Akhoundova, D.; Bacher, U.; Nilius, H.; Hoffmann, M.; Largiadèr, C.R.; Aebi, Y.; Hayoz, M.; Kronig, M.-N.; Pabst, T.
Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy. Cancers 2025, 17, 1138.
https://doi.org/10.3390/cancers17071138
AMA Style
Schüpbach A, Akhoundova D, Bacher U, Nilius H, Hoffmann M, Largiadèr CR, Aebi Y, Hayoz M, Kronig M-N, Pabst T.
Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy. Cancers. 2025; 17(7):1138.
https://doi.org/10.3390/cancers17071138
Chicago/Turabian Style
Schüpbach, Anja, Dilara Akhoundova, Ulrike Bacher, Henning Nilius, Michèle Hoffmann, Carlo R. Largiadèr, Yolanda Aebi, Michael Hayoz, Marie-Noëlle Kronig, and Thomas Pabst.
2025. "Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy" Cancers 17, no. 7: 1138.
https://doi.org/10.3390/cancers17071138
APA Style
Schüpbach, A., Akhoundova, D., Bacher, U., Nilius, H., Hoffmann, M., Largiadèr, C. R., Aebi, Y., Hayoz, M., Kronig, M.-N., & Pabst, T.
(2025). Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy. Cancers, 17(7), 1138.
https://doi.org/10.3390/cancers17071138
